These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 34967586

  • 1. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
    Hattakitpanitchakul S, Kobbuaklee S, Wudhikarn K, Polprasert C.
    Asian Pac J Cancer Prev; 2021 Dec 01; 22(12):4037-4042. PubMed ID: 34967586
    [Abstract] [Full Text] [Related]

  • 2. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
    Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R, GROM (Gruppo Romano Mielodisplasie).
    Ann Hematol; 2016 Jun 01; 95(7):1059-65. PubMed ID: 27091349
    [Abstract] [Full Text] [Related]

  • 3. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
    Castelli R, Schiavon R, Rossi V, Deliliers GL.
    Med Oncol; 2018 Apr 19; 35(5):76. PubMed ID: 29675620
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U.
    Ann Hematol; 2020 Jan 19; 99(1):7-19. PubMed ID: 31650290
    [Abstract] [Full Text] [Related]

  • 5. A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
    Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.
    Ann Hematol; 2017 Dec 19; 96(12):2025-2029. PubMed ID: 28975386
    [Abstract] [Full Text] [Related]

  • 6. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes.
    Suzuki T, Oh I, Ohmine K, Meguro A, Mori M, Fujiwara S, Yamamoto C, Nagai T, Ozawa K.
    Int J Hematol; 2015 Jan 19; 101(1):32-6. PubMed ID: 25374009
    [Abstract] [Full Text] [Related]

  • 7. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.
    J Clin Oncol; 2017 May 10; 35(14):1591-1597. PubMed ID: 28350519
    [Abstract] [Full Text] [Related]

  • 8. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
    Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P.
    Ann Hematol; 2013 May 10; 92(5):621-31. PubMed ID: 23358617
    [Abstract] [Full Text] [Related]

  • 9. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
    Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.
    Haematologica; 2019 Mar 10; 104(3):497-504. PubMed ID: 30287621
    [Abstract] [Full Text] [Related]

  • 10. Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
    Caballero JC, Dávila J, López-Pavía M, Such E, Bernal T, Ramos F, Calabuig M, Hernández Sánchez JM, Pomares H, Sánchez Barba M, Abáigar M, González B, Merchán B, Sancho-Tello R, Callejas M, Muñoz-Novas C, Cerveró C, Sanz G, Hernández Rivas JM, Díez Campelo M.
    Ther Adv Hematol; 2024 Mar 10; 15():20406207231218157. PubMed ID: 38186638
    [Abstract] [Full Text] [Related]

  • 11. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.
    Haematologica; 2001 Jan 10; 86(1):44-51. PubMed ID: 11146570
    [Abstract] [Full Text] [Related]

  • 12. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
    Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.
    Leukemia; 2016 Apr 10; 30(4):897-905. PubMed ID: 26500139
    [Abstract] [Full Text] [Related]

  • 13. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
    Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R.
    Eur J Haematol; 2002 Mar 10; 68(3):180-5. PubMed ID: 12068800
    [Abstract] [Full Text] [Related]

  • 14. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
    Nakazaki K, Nannya Y, Kurokawa M.
    Int J Hematol; 2014 Jan 10; 99(1):53-6. PubMed ID: 24307517
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA.
    Curr Med Res Opin; 2011 May 10; 27(5):951-60. PubMed ID: 21381892
    [Abstract] [Full Text] [Related]

  • 16. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
    Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, Hata T, Miyamoto T, Kawabata H, Takeuchi K, Tanaka H, Kishimoto J, Miyano S, Matsumura I, Ogawa S, Akashi K, Kanakura Y, Mitani K.
    Int J Hematol; 2022 Nov 10; 116(5):659-668. PubMed ID: 35821550
    [Abstract] [Full Text] [Related]

  • 17. Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study.
    Qu WY, Zhao L, Tan XC, Zhao YH.
    Ann Hematol; 2021 Jun 10; 100(6):1451-1457. PubMed ID: 33837816
    [Abstract] [Full Text] [Related]

  • 18. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
    Raimbault A, Itzykson R, Willems L, Rousseau A, Chapuis N, Mathis S, Clauser S, Radford-Weiss I, Bouscary D, Fontenay M, Kosmider O, Bardet V.
    Cytometry B Clin Cytom; 2019 May 10; 96(3):215-222. PubMed ID: 30963682
    [Abstract] [Full Text] [Related]

  • 19. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
    Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.
    Am J Hematol; 2018 Nov 10; 93(11):1420-1426. PubMed ID: 30152885
    [Abstract] [Full Text] [Related]

  • 20. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
    Santini V.
    Oncologist; 2011 Nov 10; 16 Suppl 3():35-42. PubMed ID: 21930833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.